Table 2. Treatment effects at 2 weeks post-PRK.
shown as change of refraction, VSOTF and higher-order aberrations for a 6mm pupil diameter relative to baseline. All data are expressed as means and standard deviations (minima and maxima in parentheses). Data in bold exhibit statistically significant differences between control eyes and those that received anti-TGFβ treatment.
| anti-TGFβ (n=4) | controls (n=7) | |
|---|---|---|
| M (spherical equivalent) [D] | 4.79 ±0.86 (4.04 to 5.68) |
5.04 ±2.11 (2.56 to 7.65) |
| J0 (0/90° astigmatism) [D] | 0.09 ±0.09 (−0.03 to 0.20) |
0.27 ±0.48 (−0.38 to 0.84) |
| J45 (45/135° astigmatism)[D] | 0.20 ±0.13 (0.05 to 0.37) |
0.30 ±0.52 (−0.20 to 1.14) |
| total HOA RMS [μm] |
0.20±0.18† (0.036 to 0.362) |
0.82±0.32 (0.477 to 1.232) |
| coma RMS [μm] |
0.08 ±0.28* (−0.13 to 0.46) |
0.48 ±0.22 (0.17 to 0.71) |
| spherical aberration RMS [μm] | 0.21 ±0.07 (0.139 to 0.279) |
0.41 ±0.40 (−0.136 to 1.001) |
| residual HOA RMS [μm] |
0.06 ±0.1† (−0.025 to 0.201) |
0.49 ±0.27 (0.196 to 0.874) |
| 6th to 10th order RMS [μm] | 0.01 ±0.01 (−0.022 to 0.297) |
0.10 ±0.09 (0.014 to 0.235) |
| log BCVSOTF | −0.27 ±0.34 (−0.65 to 0.18) |
−0.67 ±0.27 (−1.15 to −0.46) |
*
P <0.05 (inter-group differences Student's t test)
†
P <0.01 (inter-group differences Student's t test)
BCVSOTF: visual Strehl ratio, based on the optical transfer function (simulation for best spectacle correction)
total RMS: RMS of 2nd to 5th order aberrations
HOA RMS: RMS of 3rd to 5th order aberrations
coma RMS: RMS of 3rd and 5th order coma terms
residual HOA RMS: RMS of all non-coma, non-spherical HOA